BBB seminar: Colin Clyne
Targeting orphan nuclear receptors in breast cancer
Cancer Drug Discovery Laboratory, Prince Henry's Institute of Medical Research, Clayton, Victoria, Australia
Most breast cancer patients have oestrogen-dependant disease that can be treated by blocking oestrogen action or synthesis. However, for those women with oestrogen-independent disease (or those whose tumours have developed resistance to endocrine therapies), few treatments are available. Recent expression profiling has revealed several nuclear receptors – proteins related to the oestrogen receptor – to be differentially expressed in various breast cancer subtypes, and to modulate breast cancer cell function. This presents opportunities for the development of novel therapeutics, particularly for patients with oestrogen-independent disease.
Chairperson: Marit Bakke, Department of Biomedicine